NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

Apheresis and CD34+ Selection of Mobilized Peripheral Blood CD34+ Cells from Patients with DOCK8 Deficiency, LAD-1, and GATA2 Deficiency

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts




Sponsoring Institute

National Cancer Institute (NCI)

Recruitment Detail

Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: 18
Max Age: 40

Referral Letter Required


Population Exclusion(s)

Pregnant Women;


PBSC Collection;
Spectra Apheresis System;
Stem Cell Mobilization;
Natural History

Recruitment Keyword(s)



GATA2 Deficancy

Investigational Drug(s)


Investigational Device(s)




Supporting Site

National Cancer Institute


- Gene therapy is being investigated as a possible treatment for individuals with immunodeficiency diseases or other conditions that make it difficult to fight off infection. Gene therapy avoids problems with donor identification and possible rejection of bone marrow transplant by using the patient s own modified blood cells to help treat the disease. Researchers are interested in collecting stem cells from the blood of individuals with immunodeficiency diseases in order to use the cells to develop potential gene therapy treatments.


- To collect blood stem cells from patients with immunodeficiency diseases tto test our ability to correct the defects of these cells in the test tube.


- Individuals between 18 and 40 years of age with immunodeficiency diseases.

- Individuals with human immunodeficiency virus (HIV) will not be able to participate in this study.


- Participants will provide an initial blood sample for disease screening (such as hepatitis B and C, syphilis, or viruses like the Epstein-Barr virus, herpes simplex virus, or toxoplasmosis) and to check kidney and liver function.

- Starting 5 days before blood donation, participants will receive daily injections of a drug called G-CSF (granulocyte colony stimulating factor, or filgrastim), which pushes stem cells out of the bone marrow and into the bloodstream. Participants will receive the injections at the National Institutes of Health Clinical Center.

- On day 5, participants will have a single leukapheresis procedure to collect the stem cells from the blood.

- No additional treatment will be provided as part of this protocol. The cells that are collected will be used fore experiments in the lab and will not be used to treat individuals with these diseases.

--Back to Top--



a) Patient age of 18-40 years.

b) Diagnosis of DOCK8 deficiency, LAD-1, or GATA2 Deficiency:

-DOCK8 deficiency

--Homozygous or compound heterozygous mutations in the DOCK8 gene.


--Less than 10% CD18 expression on the neutrophil surface.

-GATA2 Deficiency

--Deleterious mutation of GATA2 Gene

c) Serum creatinine <1.5 mg/dL.

d) Total Bilirubin < 3mg/dl, ALT and AST < 5X upper limit of normal.

e) Ability to give informed consent.

f) Adequate venous access for peripheral apheresis, or consent to use a temporary central venous catheter for apheresis.

g) Female patients of childbearing age must have a negative urine pregnancy test within one week prior to beginning filgrastim or filgrastim biosimilar administration.


a) HIV infection.

b) Chronic hepatitis B or hepatitis C virus infection.

c) History of psychiatric disorder which may compromise compliance with protocol, or which does not allow for appropriate informed consent.

d) Active infection that is not responding to antimicrobial therapy.

e) Pregnant women may not participate per OHSRP SOP.

f) Any female who is breastfeeding as the effects of filgrastim or filgrastim biosimilar product on infants is not known.

g) Sexually active individuals capable of becoming pregnant who are unable or unwilling to use effective form(s) of contraception during the 10 days surrounding filgrastim or filgrastim biosimilar product administration and apheresis procedure(s). Effective forms of contraception include one or more of the following: intrauterine device (IUD), hormonal (birth control pills, injections, or implants), tubal ligation/hysterectomy, partner s vasectomy, barrier methods, (condom, diaphragm, or cervical cap), or abstinence. Males on the protocol must use an effective form of contraception at study entry.

h) Presence of active malignancy in another organ system other than the hematopoietic system.

i) Patients with active pulmonary disease.

j) History of hypertension that is not controlled by medication, stroke, or severe heart disease. Individuals with symptomatic angina will be considered to have severe heart disease and will not be eligible.

k) Other medical contraindications to stem cell donation (i.e., severe atherosclerosis, autoimmune disease, iritis or episcleritis, deep venous thrombosis, cerebrovascular accident).

l) Thrombocytopenia (platelets less than 50,000 per microliter) at baseline evaluation.

m) Patients receiving experimental therapy or investigational agents.

n) Sensitivity to filgrastim, to E. Coli derived products, or to a biosimilar recombinant protein to filgrastim.

o) Patients must test negative for transfusion-transmissible infectious agents, including hepatitis B (HBsAg), hepatitis C (anti-HCV), HIV (anti-HIV-1/2).

--Back to Top--


Anderlini P, K(SqrRoot)(Delta)rbling M, Dale D, Gratwohl A, Schmitz N, Stroncek D, Howe C, Leitman S, Horowitz M, Gluckman E, Rowley S, Przepiorka D, Champlin R. Allogeneic blood stem cell transplantation: considerations for donors. Blood. 1997 Aug 1;90(3):903-8.

Bauer TR Jr, Hai M, Tuschong LM, Burkholder TH, Gu YC, Sokolic RA, Ferguson C, Dunbar CE, Hickstein DD. Correction of the disease phenotype in canine leukocyte adhesion deficiency using ex vivo hematopoietic stem cell gene therapy. Blood. 2006 Nov 15;108(10):3313-20. Epub 2006 Jul 25.

Creevy KE, Bauer TR Jr, Tuschong LM, Embree LJ, Silverstone AM, Bacher JD, Romines C, Garnier J, Thomas ML 3rd, Colenda L, Hickstein DD. Mixed chimeric hematopoietic stem cell transplant reverses the disease phenotype in canine leukocyte adhesion deficiency. Vet Immunol Immunopathol. 2003 Oct 15;95(3-4):113-21.

--Back to Top--


Principal Investigator

Referral Contact

For more information:

Dennis D. Hickstein, M.D.
National Cancer Institute (NCI)
NIHBC 10 - CRC BG RM 3-3142
(240) 760-6169

Dennis D. Hickstein, M.D.
National Cancer Institute (NCI)
NIHBC 10 - CRC BG RM 3-3142
(240) 760-6169

NCI Referral Office
National Institute of Health Clinical Center (CC), 9000 Rockville Pike, Bethesda, Maryland 20892, United States: NCI Clinical Trials Referral Office

Clinical Trials Number:


--Back to Top--